Brooklyn ImmunoTherapeutics, Inc. (BTX)
After hours: 07:55PM EDT
| Previous Close | 9.12 |
| Open | 9.45 |
| Bid | 9.14 x 2200 |
| Ask | 9.24 x 1000 |
| Day's Range | 9.04 - 9.40 |
| 52 Week Range | 3.50 - 80.67 |
| Volume | 419,377 |
| Avg. Volume | 916,284 |
| Market Cap | 473.326M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- GlobeNewswire
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
Ticker Symbol to Remain “BTX”NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced it will transfer its common stock listing from the NYSE American to the Nasdaq Global Market, effective upon the market close on October 22, 2021. Brooklyn’
- GlobeNewswire
Brooklyn ImmunoTherapeutics Reports Inducement Grants
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on September 20, 2021, Roger Sidhu was granted a non-qualified stock option covering 161,300 shares of Brooklyn’s common stock (the “Time-Based Option”) and a restricted stock uni
- GlobeNewswire
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. “Roger’s extensive R&D experience, including many years in late-stage clinical developm
